A Phase 4, Double-Blind, Randomised, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa

drug protocol number
M15-574
drug sponsor
AbbVie
drug study
Adalimumab
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase